Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Procaps Group S.A. (PROC:NASDAQ), powered by AI.
Procaps Group S.A. is currently trading at $0.03. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Procaps Group S.A. on Alpha Lenz.
Procaps Group S.A.'s P/E ratio is 0.1.
“Procaps Group S.A. trades at a P/E of 0.1 (undervalued) with modest ROE of -221.9%.”
Ask for details →Procaps Group S.A. is a leading pharmaceutical company specializing in the development, manufacturing, and commercialization of pharmaceutical and nutritional products. The company is recognized for its innovation in the softgel and related technologies, which are critical for creating advanced dosage forms and drug delivery systems. With an emphasis on improving health outcomes, Procaps Group serves a diverse range of sectors, including prescription medications, over-the-counter products, and a variety of nutritional supplements. One of the key features of Procaps Group is its commitment to research and development, which has positioned it as a pioneer in the Latin American pharmaceutical industry. Operating with a global footprint, the company supplies its products to more than 50 countries worldwide, impacting industries such as healthcare, wellness, and nutrition. Procaps Group S.A. holds a significant place in the pharmaceutical market due to its focus on technological advancements and its ability to meet global health demands through strategic partnerships and supply chain efficiencies. Its role is particularly vital in supporting disease prevention and management through its wide array of innovative health solutions.
“Procaps Group S.A. trades at a P/E of 0.1 (undervalued) with modest ROE of -221.9%.”
Ask for details →Procaps Group S.A. (ticker: PROC) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 5,500 employees. Market cap is $3M.
The current price is $0.025 with a P/E ratio of 0.06x and P/B of -2.7x.
ROE is -221.90% and operating margin is 9.51%. Annual revenue is $410M.